Bernd served as Chairman and CEO of Antylia Scientific from 2014 through December 2021. Before joining Antylia Scientific, Bernd served as President and CEO of Qualicaps, a provider of capsule manufacturing and processing equipment for pharmaceutical companies, which sold to Mitsubishi Chemical Holdings in 2013.
Prior to Qualicaps, he was Chief Commercial Operations Officer at Life Technologies Corporation, where he was responsible for its $3.5 billion global business. Bernd held prior leadership roles with Invitrogen Corporation (a predecessor of Life Technologies) and with GE Medical Systems.
Prior to joining Antylia Scientific in November 2015, Jon co-founded and served as the Executive Vice President of Devicor Medical Products, a GTCR-portfolio company sold to the Danaher Corporation in November 2014. Prior to Devicor, Jon was a Managing Director in the Healthcare group at the Royal Bank of Scotland plc.
Earlier in his career, Jon had numerous roles in Corporate Development and M&A with Cardinal Health, Dresdner Kleinwort Wasserstein (formerly Wasserstein Perella) and Deutsche Bank (formerly BT Wolfensohn).
Dean is head of the Healthcare group at GTCR and has been instrumental in building the firm’s expertise in life sciences and medical devices. In addition to serving as a Director of Antylia Scientific, he is currently a Director of Albany Molecular, Cebatech, Cedar Gate Technologies, Corza Health, Maravai LifeSciences, Riverchase Dermatology, Regatta Medical, Rx30, Sotera, TerSera and XIFIN. Dean was previously a Director of past GTCR investments, including Actient Pharmaceuticals, ATI Physical Therapy, Convergex, Cord Blood Registry, Crealta Pharmaceuticals, Curo Health Services, Dash, Devicor Medical Products, GreatCall, Ovation Pharmaceuticals, Managed Healthcare Associates and Polypore.
Dean’s interest in the community is evident by his strong support of WBEZ Chicago Public Media, a non-commercial, public radio station financed primarily by listener contributions, where he serves as a board member and chair of the finance committee.
In addition to serving as Director of Antylia Scientific, Sean currently is a Director of Albany Molecular Research, Ceba-Tech, Cedar Gate Technologies, Corza Health, Maravai LifeSciences, Regatta, Riverchase Dermatology, Sotera and Transaction Data Systems. He was instrumental in GTCR’s past investments in Cord Blood Registry, Devicor Medical Products, Graceway Pharmaceuticals and Ovation Pharmaceuticals.
In addition to serving as a Director of Antylia Scientific, he is currently a Director of Albany Molecular Research, Corza Health, Maravai LifeSciences, TerSera and XIFIN.
Ben was previously a Director of past GTCR investments such as Actient Pharmaceuticals and Cord Blood Registry, Crealta Pharmaceuticals, Devicor Medical Products, GeneraMedix and Sterigenics. In addition, Ben was involved in transactions with past GTCR investments ATI Physical Therapy and Graceway Pharmaceuticals.
Ben is active in the community and serves on the executive board of Spark Program, a national non-profit that provides transformative apprenticeships for at-risk middle-school students.
Prior to Thermo Fisher, Mr. Jafry held leadership positions in various General Electric (GE) businesses, including plastics, energy and infrastructure, and was based in various locations across the US, the Netherlands and Switzerland. In addition to serving as a Director of Antylia Scientific, Mr. Jafry also serves on the Board of Directors of Zimmer Biomet, a global leader in orthopedics.
Greg most recently served as CEO at NuVasive, a world leader in minimally invasive spine surgery technology. Prior to that, he was CEO at Life Technologies—formerly Invitrogen—which he grew into a global life sciences powerhouse that was acquired by Thermo Fisher Scientific. He spent the first part of his career with the General Electric Company in a variety of executive roles.
In addition to serving as a Director of Antylia Scientific, Lucier remains the Chairman of Nuvasive, and serves on several public and private company boards, including Catalent, a leader in advanced pharmaceutical manufacturing services, Dentsply Sirona, a global provider of professional dental products and technologies, and Epic Sciences, a venture-backed company revolutionizing the use of cellular imaging to change cancer therapy.